

FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY

December 1, 2003

OFFICIAL

TO: Examiner Ruixiang Li
Group 1646
(703) 306-0282

RECEIVED
CENTRAL FAX CENTER

FROM Justin D. Karjala
Celera Genomics Corp.
(240) 453-3812

DEC 01 2003

FAX NO: (703)872-9306

OF PAGES (incl. cover): 6

Re: U.S. Serial No. 09/900,448, filed July 9, 2001
Entitled "ISOLATED HUMAN SECRETED PROTEINS, NUCLEIC ACID
MOLECULES ENCODING HUMAN SECRETED PROTEINS, AND USES
THEREOF"
Atty. Docket No.: CL001272

A Preliminary Amendment (Restriction Election) and a Petition for a One-Month
Extension of Time in the above-identified application follows.

The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.

PTO/SB/22 (10-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)		Docket Number (Optional) CL001272
In re Application of Toni CECCARDI et al.		
Application Number 09/900,448		Filed July 9, 2001
For ISOLATED HUMAN SECRETED PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN SECRETED...		
Group Art Unit 1646		Examiner R. Li

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.

The requested extension and appropriate non-small-entity fee are as follows (check time period desired):

<input checked="" type="checkbox"/> One month (37 CFR 1.17(a)(1))	\$110 Fee Code 115	\$ <u>110.00</u>
<input type="checkbox"/> Two months (37 CFR 1.17(a)(2))	\$410 Fee Code 116	\$ _____
<input type="checkbox"/> Three months (37 CFR 1.17(a)(3))	\$930 Fee Code 117	\$ _____
<input type="checkbox"/> Four months (37 CFR 1.17(a)(4))	\$1450 Fee Code 118	\$ _____
<input type="checkbox"/> Five months (37 CFR 1.17(a)(5))	\$1970 Fee Code 128	\$ _____

☐ Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$ _____.

☐ A check in the amount of the fee is enclosed.

☐ Payment by credit card. Form PTO-2038 is attached.

☒ The Commissioner has already been authorized to charge fees in this application to a Deposit Account.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 50-0970.

I have enclosed a duplicate copy of this sheet.

I am the ☐ applicant/inventor


☐ assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

☒ attorney or agent of record.

☐ attorney or agent under 37 CFR 1.34(a). Registration number if acting under 37 CFR 1.34(a) _____.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

December 1, 2003
 Date


 Signature
Justin D. Karjala, Reg. No. 43,704
 Typed or printed name

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ Total of _____ forms are submitted.

Burden Hour Statement: This form is estimated to take 0.1 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.